Head to Head Analysis: Spectral AI (MDAI) versus Its Peers

Spectral AI (NASDAQ:MDAI) is one of 236 publicly-traded companies in the “Surgical & medical instruments” industry, but how does it contrast to its rivals? We will compare Spectral AI to similar businesses based on the strength of its dividends, valuation, earnings, institutional ownership, risk, analyst recommendations and profitability.

Valuation & Earnings

This table compares Spectral AI and its rivals gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Spectral AI	$18.06 million	-$20.85 million	-1.11
Spectral AI Competitors	$1.02 billion	$9.23 million	-8.65

Spectral AI’s rivals have higher revenue and earnings than Spectral AI. Spectral AI is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Insider & Institutional Ownership

67.1% of Spectral AI shares are owned by institutional investors. Comparatively, 48.0% of shares of all “Surgical & medical instruments” companies are owned by institutional investors. 56.7% of Spectral AI shares are owned by company insiders. Comparatively, 15.1% of shares of all “Surgical & medical instruments” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Risk & Volatility

Spectral AI has a beta of 0.48, meaning that its stock price is 52% less volatile than the S&P 500. Comparatively, Spectral AI’s rivals have a beta of 0.46, meaning that their average stock price is 54% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations for Spectral AI and its rivals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spectral AI	0	0	3	1	3.25
Spectral AI Competitors	1877	4833	9072	263	2.48

Spectral AI presently has a consensus price target of $4.50, indicating a potential upside of 202.01%. As a group, “Surgical & medical instruments” companies have a potential upside of 19.02%. Given Spectral AI’s stronger consensus rating and higher probable upside, analysts clearly believe Spectral AI is more favorable than its rivals.

Profitability

This table compares Spectral AI and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Spectral AI	-89.85%	N/A	-104.64%
Spectral AI Competitors	-548.75%	-134.14%	-26.49%

Summary

Spectral AI beats its rivals on 9 of the 12 factors compared.

Spectral AI Company Profile

Spectral AI, Inc., an artificial intelligence (AI) company, focuses on developing predictive medical diagnostics in the United States. The company develops medical diagnostics for faster and accurate treatment decisions in wound care with applications involving patients with burns and diabetic foot ulcers. Its products include DeepView System, a predictive analytics platform integrated with the predictive AI-Burn, which combines AI algorithms and multispectral imaging (MSI) imaging for an assessment of wound healing potential and offers clinicians an objective and immediate assessment of a wound’s healing potential prior to treatment or other medical intervention; and DeepView SnapShot M, a handheld, portable, and wireless diagnostic tool, that provides a potential enhanced and expanded use for the government and emergency care, first responders, and potentially home health care professionals. The company is headquartered in Dallas, Texas.